|
|
| Product Name: | CI 934 | | Synonyms: | CI 934;1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;PD-114843;Aids007688;Aids-007688;Quinolone cl-934;3-Quinolinecarboxylic acid, 1-ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-;Merafloxacin (CI-934) | | CAS: | 91188-00-0 | | MF: | C19H23F2N3O3 | | MW: | 379.4 | | EINECS: | | | Product Categories: | | | Mol File: | 91188-00-0.mol |  |
| | CI 934 Chemical Properties |
| Melting point | 200-220.45 °C | | Boiling point | 545.8±50.0 °C(Predicted) | | density | 1.304±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 11.11 mg/mL (29.28 mM; ultrasonic and adjust pH to 3 with HCl) | | pka | 6.44±0.50(Predicted) |
| | CI 934 Usage And Synthesis |
| Biological Activity | Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria[1][2].
Merafloxacin (5-80 μM) dose-dependently inhibits programmed -1 ribosomal frameshifting (-1 PRF) of SARS-CoV-2, SARS-CoV, hCoVO-C43, and hCoV-HKU1, with IC50s of 19.6 μM, 19.5 μM, 29.7 μM, and 38.6 μM, respectively[1]. | | References | [1]. Sun Y, et, al. Restriction of SARS-CoV-2 Replication by Targeting Programmed -1 Ribosomal Frameshifting In Vitro. bioRxiv. 2020 Oct 21;2020.10.21.349225. [2]. Mandell W, et, al. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother. 1986 May;29(5):852-7. |
| | CI 934 Preparation Products And Raw materials |
|